Literature DB >> 25036544

Photodynamic therapy for choroidal hemangioma unresponsive to ranibizumab.

Li-Wei Chan1, Yi-Ting Hsieh.   

Abstract

PURPOSE: To report a patient with circumscribed choroidal hemangioma with serous macular detachment successfully treated with photodynamic therapy (PDT) after being unresponsive to treatment with intravitreal ranibizumab. CASE REPORT: A 63-year-old Asian woman was incidentally found to have a circumscribed choroidal hemangioma without symptoms in the left eye during a routine health examination. Blurred vision of the left eye developed 3.5 years later, and a serous macular detachment was observed. Two consecutive intravitreal ranibizumab injections were administered, but the subretinal fluid (SRF) persisted and the vision did not improve. One PDT session was then given, and the SRF resolved completely within 1 month. The best-corrected visual acuity improved from 20/50 before treatment to 20/25 at 4 months after the PDT. The tumor thickness also decreased from 3.84 mm before treatment to 2.86 mm at 14 months after PDT.
CONCLUSIONS: Circumscribed choroidal hemangioma with serous macular detachment may not respond to anti-vascular endothelial growth factor agents. Photodynamic therapy may be an effective choice in such cases to remove SRF and improve vision.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25036544     DOI: 10.1097/OPX.0000000000000349

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  2 in total

Review 1.  Circumscribed choroidal hemangioma: A case report and literature review.

Authors:  Morgan Berry; Linda J H Lucas
Journal:  J Optom       Date:  2016-02-10

2.  Clinical outcomes and predictors of response to photodynamic therapy in symptomatic circumscribed choroidal hemangioma: A retrospective case series.

Authors:  Yeen-Fey Ho; Anne Chao; Kuan-Jen Chen; An-Ning Chao; Nan-Kai Wang; Laura Liu; Yen-Po Chen; Yih-Shiou Hwang; Wei-Chi Wu; Chi-Chun Lai; Tun-Lu Chen
Journal:  PLoS One       Date:  2018-05-31       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.